Menovazin

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT MENOVASIN

Composition:

Active substances: benzocaine, procaine hydrochloride, racemic menthol;

1 g of gel contains: benzocaine 10 mg, procaine hydrochloride 10 mg, racemic menthol 25 mg;

Excipients: carbomer, triethanolamine, ethanol 96%, purified water.

Pharmaceutical form. Gel.

Main physicochemical characteristics: homogeneous gel, colorless to slightly yellowish, transparent or slightly opalescent, with a menthol odor.

Pharmacotherapeutic group. Products applied locally in joint and muscular pain. ATC code M02AX.

Pharmacological properties

Pharmacodynamics. Menovazin is a combined medicinal agent, and its properties are determined by the action of active components. The agent has anti-itch and local anesthetic effects. After application to the skin and mucous membranes, it causes irritation of nerve endings, accompanied by a sensation of cold and tingling. It exerts a mild analgesic and distracting effect.

Pharmacokinetics. When applied locally, the drug does not enter the systemic circulation.

Clinical characteristics

Indications. The medicinal product is indicated for: neuralgias, myalgias, arthralgias; dermatoses accompanied by pruritus.

Contraindications. Menovazin is contraindicated in case of hypersensitivity to procaine and to other components of the medicinal product.

Special precautions. Do not apply to damaged skin, skin with allergic manifestations, or facial skin.

Interaction with other medicinal products and other forms of interactions

Components of the medicinal product (procaine, anestezin) reduce the antibacterial effect of sulfonamide drugs. Menovazin gel may enhance the effects of medicinal products with local anesthetic action.

Inform your doctor about the concurrent use of any other medicinal products.

Usage Notes

Use during pregnancy or breastfeeding. There is no experience with the use of the medicinal product during pregnancy or breastfeeding.

Ability to affect reaction rate when driving or operating machinery. Has no effect.

Dosage and Administration

The medicinal product is for topical use.

Apply the gel in an even layer to affected areas 2–3 times daily. The duration of treatment depends on the form and severity of the disease, the response to the medicinal product, and the treatment regimen (monotherapy or in combination with other medicinal products).

The maximum daily dose is 9 g.

Children. Do not use in children under 12 years of age.

Overdose

With prolonged use, the following may occur: dizziness, general weakness, decreased arterial blood pressure, and allergic reactions. If such symptoms occur, discontinue use of the medicinal product, wash off any remaining gel from the skin surface with water, and administer symptomatic therapy.

Adverse reactions.

Possible allergic reactions (hyperemia, skin irritation, itching sensation, rash, swelling, urticaria), contact dermatitis.

Reporting of adverse reactions after drug registration is highly important. It enables continuous monitoring of the benefit-risk balance of this medicinal product. Medical and pharmaceutical professionals, as well as patients or their legal representatives, should report all suspected adverse reactions and lack of efficacy via the Automated Pharmacovigilance Information System at the following link: https://aisf.dec.gov.ua

Shelf life. 2 years.

Storage conditions. Store at temperatures not exceeding 25 °C. Keep out of reach of children.

Packaging. 40 g in a tube. One tube per cardboard box.

Supply category. Over-the-counter (without prescription).

Manufacturer/Marketing Authorization Holder. Ternopharm LLC.

Manufacturer's location and address of business activity / Marketing Authorization Holder's location. 4, Fabrychna Street, Ternopil, 46010, Ukraine.

Tel./Fax: (0352) 521-444, www.ternopharm.com.ua